Cited by 283Opioid Use Disorder TreatmentPain Management and Opioid UseNeuropeptides and Animal Physiology

The DOI matches its Crossref record.

Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Walsh, S L, Preston, K L, Bigelow, G E, Stitzer, M L·1995·The Journal of Pharmacology and Experimental Therapeutics

Open this paper in CoChat — free account

Abstract

Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence. This study compared the acute subjective and physiological effects of sublingual buprenorphine to those of p.o. methadone over a wide range of doses and compared the ability of both drugs to alter the effects of an opioid challenge. Male inpatient volunteers (n = 9) with histories of opioid abuse participated in this double-blind, double-dummy study. Sublingual buprenorphine (0, 0.5, 2, 8, 16 and 32 mg) and p.o. methadone (3.75, 15 and 60 mg) were administered once weekly according to a Latin-square design, and subjects were monitored on a variety of physiological and subjective measures. Twenty-four hours later, subjects were tested with ascending doses of i.m. hydromorphone (0, 1 and 4 mg) given 45 min apart. Buprenorphine and methadone produced typical opioid agonist effects of long duration, including pupillary constriction, respiratory depression and elevations on subject-rated and observer-rated indices of euphoria, sedation and opioid-like symptoms. The buprenorphine dose-effect curves were nonlinear and maximal effects for most physiological and subjective measures were observed between 4 and 8 mg, with no greater effects observed at higher doses. The methadone dose-effect curves were linear across the range of doses tested. High doses of buprenorphine and methadone both attenuated the response to hydromorphone challenge 24 hr later. These data indicate that there is a ceiling on the effects of buprenorphine in humans that may reduce its abuse liability and increase its safety, and indicate that opioid blockade occurs after acute administration of buprenorphine or methadone.

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)10510-7

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Still being checked.

Sorted by citations

Items 101–200 of 278

An injection depot formulation of buprenorphine: extended biodelivery and effects
Sigmon, S. C., Moody, D. E., Nuwayser, E. S., & Bigelow, G. E. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01348.x · Cited by 54
Self-citation
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
Jones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A., & Laffont, C. M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00957-0 · Cited by 53
Benefit-Risk Analysis of Buprenorphine for Pain Management
Hale, M. E., Garofoli, M., & Raffa, R. B. (2021) · Journal of Pain Research · doi:10.2147/jpr.s305146 · Cited by 54
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
Strain, E. C., WALSH, S. L., & Bigelow, G. E. (2001) · Psychopharmacology · doi:10.1007/s002130100920 · Cited by 53
Self-citation
Psychotropic Drugs Used in Anesthesia Practice
Zacny, J. P., & Galinkin, J. L. (1999) · Anesthesiology · doi:10.1097/00000542-199901000-00033 · Cited by 51
Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol
Rosenblum, A., Cruciani, R. A., Strain, E. C., Cleland, C. M., Herman Joseph, P., Magura, S., Marsch, L. A., McNicholas, L. F., Savage, S. R., Sundaram, B. A., et al. (2012) · Journal of Opioid Management · doi:10.5055/jom.2012.0137 · Cited by 51
Intravenous Buprenorphine Self-Administration by Detoxified Heroin Abusers
Comer, S. D., Collins, E. D., & Fischman, M. W. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.266 · Cited by 51
Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland
Genberg, B. L., Gillespie, M. A., Schuster, C. R., Johanson, C., Astemborski, J. A., Kirk, G. D., Vlahov, D., & Mehta, S. H. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.08.008 · Cited by 50
Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder
Laffont, C. M., Goméni, R., Heidbreder, C. A., Jones, J. P., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.665 · Cited by 50
Pharmacokinetics of radiotracers in human plasma during positron emission tomography
Cumming, P. D., Yokoi, F., Chen, A., Deep, P., Dagher, A., Reutens, D. C., Kapczinski, F. P., Wong, D. F., & GJEDDE, A. H. (1999) · Synapse · doi:10.1002/(sici)1098-2396(199911)34:2 · Cited by 39
Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers
Umbricht, A., Huestis, M. A., Cone, E. J., & Preston, K. L. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138766.15858.c6 · Cited by 49
Self-citation
Effect of μ-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats
Walker, J. S., Chandler, A., Wilson, J. L., Binder, W., & Day, R. O. (1996) · Inflammation Research · doi:10.1007/bf02342227 · Cited by 49
Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics
Remesic, M., Hruby, V. J., Porreca, F., & Lee, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00090 · Cited by 48
A dose–effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers
Mintzer, M. Z., Correia, C. J., & Strain, E. C. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.12.008 · Cited by 48
The effects of buprenorphine in buprenorphine-maintained volunteers
Strain, E. C., WALSH, S. L., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1997) · Psychopharmacology · doi:10.1007/s002130050199 · Cited by 48
Self-citation
Case Series of Successful Postoperative Pain Management in Buprenorphine Maintenance Therapy Patients
Leighton, B. L., & Crock, L. W. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002498 · Cited by 47
Rational Use of Sublingual Opioids in Palliative Medicine
Reisfield, G. M., & Wilson, G. R. (2007) · Journal of Palliative Medicine · doi:10.1089/jpm.2006.0150 · Cited by 47
Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers
Zacny, J. P., Conley, K., & Galinkin, J. L. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36921-6 · Cited by 46
Treatment of Heroin (Diamorphine) Addiction
Gonzalez, G. M., Oliveto, A. H., & Kosten, T. R. (2002) · Drugs · doi:10.2165/00003495-200262090-00004 · Cited by 46
Opioid Addicts at Admission vs. Slow-Release Oral Morphine, Methadone, and Sublingual Buprenorphine Maintenance Treatment Participants
Giacomuzzi, S. M., Kemmler, G., Ertl, M., & Riemer, Y. (2006) · Substance Use & Misuse · doi:10.1080/10826080500391845 · Cited by 45
Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
Comer, S. D., Sullivan, M. A., & Walker, E. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090423 · Cited by 44
Transdermal Buprenorphine to Switch Patients from Higher Dose Methadone to Buprenorphine without Severe Withdrawal Symptoms
Hess, M., Boesch, L., Leisinger, R., & Stohler, R. (2011) · American Journal on Addictions · doi:10.1111/j.1521-0391.2011.00159.x · Cited by 42
Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance
Greenwald, M. K., Johanson, C., & Schuster, C. R. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00032-0 · Cited by 41
Examining the limits of the buprenorphine interdosing interval: daily, every‐third‐day and every‐fifth‐day dosing regimens
Petry, N. M., Bickel, W. K., & Badger, G. J. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9668234.x · Cited by 41
Morphine-Infused Silver Sulfadiazine (MISS) Cream for Burn Analgesia: A Pilot Study
Long, T. D., Cathers-Schiffman, T. A., Twillman, R. K., O’Donnell, T., Garrigues, N. W., & Jones, T. (2001) · Journal of Burn Care & Rehabilitation · doi:10.1097/00004630-200103000-00006 · Cited by 40
Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients?
Vignau, J., Duhamel, A., Catteau, J., Legal, G., Huynh, A., Grailles, I., Beauvillain, J., Petit, P., Beauvillain, P., & Parquet, P. J. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00189-1 · Cited by 39
Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist
Raffa, R. B., & Ding, Z. (2007) · Acute Pain · doi:10.1016/j.acpain.2007.07.002 · Cited by 39
Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry
Rosas, M. E. R., Lofwall, M. R., Strain, E. C., Siluk, D., & Wainer, I. W. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.11.025 · Cited by 39
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence
Barnwal, P., Das, S., Mondal, S., Ramasamy, A., Maiti, T., & Saha, A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316681984 · Cited by 41
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
Hjelmström, P., Nordbeck, E. B., & Tiberg, F. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1706552 · Cited by 39
Treating Chronic Pain with Buprenorphine—The Practical Guide
Case, A. A., Kullgren, J. G., Anwar, S., Pedraza, S. L., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00910-8 · Cited by 39
Pharmacologic Management of Cancer Pain
Cleary, J. F., & Carbone, P. P. (1995) · Hospital Practice · doi:10.1080/21548331.1995.11443287 · Cited by 39
Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures
Kelly, T. H., Stoops, W. W., Perry, A. S., Prendergast, M., & Rush, C. R. (2003) · Behavioral and Cognitive Neuroscience Reviews · doi:10.1177/1534582303262095 · Cited by 39
Evaluation of an injection depot formulation of buprenorphine: placebo comparison
Sigmon, S. C., Wong, C. J., Chausmer, A. L., Liebson, I. A., & Bigelow, G. E. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00834.x · Cited by 39
Self-citation
Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges
Zweben, J. E., Sorensen, J. L., Shingle, M., & Blazes, C. K. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000789 · Cited by 38
High buprenorphine-related mortality is persistent in Finland
Kriikku, P., Häkkinen, M., & Ojanperä, I. A. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.08.010 · Cited by 38
Risk identification, risk assessment, and risk management of abusable drug formulations
Wright, C., Kramer, E. D., Zalman, M.-A., Smith, M. Y., & Haddox, J. D. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.12.012 · Cited by 38
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients
Eissenberg, T., Johnson, R. E., Bigelow, G. E., WALSH, S. L., Liebson, I. A., Strain, E. C., & Stitzer, M. L. (1997) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(97)01347-1 · Cited by 38
Self-citation
Thienorphine Is a Potent Long-Acting Partial Opioid Agonist: A Comparative Study with Buprenorphine
Yu, G., Yue, Y.-J., Cui, M., & Gong, Z. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099937 · Cited by 37
Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients
Mercadante, S., Ferrera, P., & Villari, P. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0169-8 · Cited by 37
Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment
Stoops, W. W., Lofwall, M. R., Nuzzo, P. A., Craig, L., Siegel, A. J., & WALSH, S. L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2739-4 · Cited by 36
Self-citation
Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers
Bai, S. A., Xiang, Q., & Finn, A. L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.016 · Cited by 36
Determination of Naltrexone and 6- -Naltrexol in Plasma by Solid-Phase Extraction and Gas Chromatography-Negative Ion Chemical Ionization-Mass Spectrometry
Huang, W., Moody, D. E., Foltz, R. L., & WALSH, S. L. (1997) · Journal of Analytical Toxicology · doi:10.1093/jat/21.4.252 · Cited by 36
Self-citation
Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway
Nechanská, B., Mravčík, V., Skurtveit, S. O., Lund, I. O., Gabrhelík, R., Engeland, A., & Handal, M. (2018) · Addiction · doi:10.1111/add.14192 · Cited by 35
Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain
Leri, F., Zhou, Y., Goddard, B., Levy, A., Jacklin, D. L., & Kreek, M. J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.09.004 · Cited by 35
Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine
Belcheva, M. M., Bohn, L., Ho, M. T., Johnson, F. E., Yanai, J., Barron, S., & Coscia, C. J. (1998) · Developmental Brain Research · doi:10.1016/s0165-3806(98)00117-5 · Cited by 35
AWMF-Leitlinien: Postakutbehandlung bei Störungen durch Opioide
Havemann‐Reinecke, U., Küfner, H., Schneider, U., Günthner, A., Schalast, N., & Vollmer, H. C. (2004) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2004.04.02 · Cited by 34
Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence
Kjome, K. L., & Moeller, F. G. (2011) · Substance Abuse Research and Treatment · doi:10.4137/sart.s5452 · Cited by 34
The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15‐year retrospective cohort study
Bharat, C., Larney, S., Barbieri, S., Dobbins, T., Jones, N. R., Hickman, M., Gisev, N., Ali, R. L., & Degenhardt, L. J. (2021) · Addiction · doi:10.1111/add.15514 · Cited by 36
Enhanced Buprenorphine Analgesia with the Addition of Ultra-low-dose Naloxone in Healthy Subjects
Vincente, S. F. L., White, J. M., Somogyi, A. A., Bochner, F., & Chapleo, C. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100262 · Cited by 33
Buprenorphine Implant for Opioid Addiction
Ling, W. W. (2012) · Pain Management · doi:10.2217/pmt.12.26 · Cited by 33
Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years
Blanco-Gandía, M. C., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.007 · Cited by 35
A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence*
Petry, N. M., Bickel, W. K., & Badger, G. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70039-1 · Cited by 33
Intravenous and Oral l-α-Acetylmethadol: Pharmacodynamics and Pharmacokinetics in Humans
WALSH, S. L., Johnson, R. E., Cone, E. J., & Bigelow, G. E. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37363-x · Cited by 33
Self-citation
Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
Webster, L. R., Gruener, D., Kirby, T., Xiang, Q., Tzanis, E. L., & Finn, A. L. (2016) · Pain Medicine · doi:10.1093/pm/pnv110 · Cited by 32
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users
Jones, J. D., Sullivan, M. A., Vosburg, S. K., Manubay, J. M., Mogali, S., Metz, V. E., & Comer, S. D. (2014) · Addiction Biology · doi:10.1111/adb.12163 · Cited by 32
Buprenorphine and Opioid Antagonism, Tolerance, and Naltrexone-Precipitated Withdrawal
Paronis, C. A., & Bergman, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173823 · Cited by 32
Bridging waitlist delays with Interim Buprenorphine Treatment: Initial feasibility
Sigmon, S., Meyer, A. C., Hruska, B., Ochalek, T. A., Rose, G. L., Badger, G., Brooklyn, J., Heil, S., Higgins, S., Moore, B. A., et al. (2015) · Addictive Behaviours · doi:10.1016/j.addbeh.2015.07.030 · Cited by 35
A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration
Kalluri, H. V., Zhang, H., Caritis, S. N., & Venkataramanan, R. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13368 · Cited by 31
Prescription Pain Medication Dependence
Dodrill, C. L., Helmer, D. A., & Kosten, T. R. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020260 · Cited by 30
Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies
Li, X., Shorter, D. I., & Kosten, T. R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.955469 · Cited by 30
Concomitant drugs with buprenorphine user deaths
Mariottini, C., Kriikku, P., & Ojanperä, I. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108345 · Cited by 30
Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
Laffont, C. M., Ngaimisi, E., Gopalakrishnan, M., Ivaturi, V. D., Young, M. A., Greenwald, M. K., & Heidbreder, C. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1052113 · Cited by 30
Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?
Pavlic, M., Libiseller, K., Grubwieser, P., & Rabl, W. (2005) · International Journal of Legal Medicine · doi:10.1007/s00414-005-0544-x · Cited by 30
Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids
Hale, M. E., Urdaneta, V., Kirby, T., Xiang, Q., & Rauck, R. L. (2017) · Journal of Pain Research · doi:10.2147/jpr.s120170 · Cited by 29
Methadone therapy for opioid dependence.
Krambeer, L. L., McKnelly, W., Gabrielli, W. F., & Penick, E. C. (2001) · PubMed · Cited by 29
Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center
Toce, M. S., Burns, M. M., & O’Donnell, K. A. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1244337 · Cited by 28
Efficacy of continuing medical education to reduce the risk of buprenorphine diversion
Lofwall, M. R., Wunsch, M. J., Nuzzo, P. A., & WALSH, S. L. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.04.008 · Cited by 28
Self-citation
Continuous Perioperative Sublingual Buprenorphine
Silva, M. J., & Rubinstein, A. L. (2016) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2016.1231734 · Cited by 28
Buprenorphine-Containing Treatments
Robinson, S. E. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00001 · Cited by 28
Induction of patients with moderately severe methadone dependence onto buprenorphine
Glasper, A., Reed, L., de Wet, C., Gossop, M., & Bearn, J. (2005) · Addiction Biology · doi:10.1080/13556210500123126 · Cited by 27
Determination of Buprenorphine, Fentanyl and LSD in Whole Blood by UPLC-MS-MS
Berg, T., Jørgenrud, B., & Strand, D. H. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bkt005 · Cited by 27
Toxicologic Aspects of Heroin Substitution Treatment
Cone, E. J., & Preston, K. L. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200204000-00001 · Cited by 27
Self-citation
Buprenorphine in the Treatment of Opiate Dependence: Its Pharmacology and Social Context of Use in the U.S.
Wesson, D. R. (2004) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2004.10400047 · Cited by 27
III. Old dog'new (ma)trix † †Declaration of interest. Dr Collett was a member of the Transtec Advisory Board (two Meetings) organised by Napp Pharmaceuticals and has been in receipt of three travel grants from that company over the last 5 years. Dr Budd was a member of the Transtec Advisory Boards of Napp Pharmaceuticals and Grunenthal GmbH and has received lecture and travel expenses from both companies.
Budd, K., & Collett, B. J. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg133 · Cited by 26
Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology
Mooney, L. J., Nielsen, S., Saxon, A. J., Hillhouse, M. P., Thomas, C., Hasson, A. L., Stablein, D. M., McCormack, J., Lindblad, R., & Ling, W. W. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.11.002 · Cited by 25
Prenatal administration of buprenorphine in the rat: Effects on the rest-activity cycle at 22 and 30 days of age
Hutchings, D. E., Hamowy, A. S., Williams, E. M., & Zmitrovich, A. C. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00287-0 · Cited by 25
Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement.
Sigmon, S. C. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.1.1 · Cited by 23
Evidence for Continuing Buprenorphine in the Perioperative Period
Li, A. H.-Y., Schmiesing, C. A., & Aggarwal, A. K. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000858 · Cited by 23
Liquid chromatographic–electrospray ionization mass spectrometric quantitative analysis of buprenorphine, norbuprenorphine, nordiazepam and oxazepam in rat plasma
Pirnay, S., Hervé, F., Bouchonnet, S., Perrin, B., Baud, F. J., & Ricordel, I. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.02.020 · Cited by 23
Buprenorphine dosing regime in the management of out‐patient heroin withdrawal
Lintzeris, N. (2002) · Drug and Alcohol Review · doi:10.1080/09595230220119309 · Cited by 23
Comorbid Pain and Opioid Addiction: Psychosocial and Pharmacological Treatments
Wachholtz, A., Ziedonis, D. M., & Gonzalez, G. M. (2011) · Substance Use & Misuse · doi:10.3109/10826084.2011.559606 · Cited by 22
The opioid epidemic and pregnancy
Raymond, B. L., Kook, B. T., & Richardson, M. G. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000590 · Cited by 21
Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days
Groß, A., Jacobs, E. A., Petry, N. M., Badger, G. J., & Bickel, W. K. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00227-1 · Cited by 21
Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder
Maremmani, I., Demattéis, M., Gorzelańczyk, E. J., Mugelli, A., Walcher, S., & Torrens, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175575 · Cited by 21
Buprenorphine: prospective novel therapy for depression and PTSD
Madison, C. A., & Eitan, S. (2020) · Psychological Medicine · doi:10.1017/s0033291720000525 · Cited by 21
Discriminative Stimulus Effects of l-α-Acetylmethadol (LAAM), Buprenorphine and Methadone in Morphine-Treated Rhesus Monkeys
Brandt, M. R., Cabansag, S. R., & France, C. P. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36839-9 · Cited by 19
Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount
Jones, J. D., Manubay, J. M., Mogali, S., Metz, V. E., Madera, G., Martinez, S., Mumtaz, M., & Comer, S. D. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.033 · Cited by 18
Treatment Outcome for Flexible Dosing Buprenorphine Maintenance Treatment
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. P. G. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.643988 · Cited by 17
Buprenorphine Buccal Film for Chronic Pain Management
Hale, M. E., Gimbel, J. S., & Rauck, R. L. (2020) · Pain Management · doi:10.2217/pmt-2020-0013 · Cited by 19
Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies
Wachholtz, A., Gonzalez, Boyer, A., Naqvi, Rosenbaum, V., & Ziedonis (2011) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s12944 · Cited by 16
The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users
Jones, J. D., Madera, G., & Comer, S. D. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.04.012 · Cited by 16
Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
González-Saiz, F., Rojas, Ó. L. L., Trujols, J., Alcaraz, S., Siñol, N., & Cobos, J. P. D. L. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.10.035 · Cited by 15
Development of Biodegradable Drug Delivery System to Treat Addiction
Mandal, T. K. (1999) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-100102237 · Cited by 15
Relative Potency of levo-α-Acetylmethadol and Methadone in Humans under Acute Dosing Conditions
Eissenberg, T., Stitzer, M. L., Bigelow, G. E., Buchhalter, A. R., & Walsh, S. L. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38221-7 · Cited by 14
Self-citation
An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals
Faysal, J. A., Noor‐E‐Alam, M., Young, G. J., Lo‐Ciganic, W., Goodin, A. J., Huang, J. L., Wilson, D. L., Park, T. W., & Hasan, M. M. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108493 · Cited by 14
Discovery of a functionally selective serotonin receptor (5-HT 1A R) agonist for the treatment of pain
Ullrich, A., Schneider, J., Bráz, J. M., Neu, E., Staffen, N., Stanek, M., Bláhová, J., Hove, T. T., Albert, T., Allikalt, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv9267 · Cited by 17
Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine
Kuel, C.-H., Liu, K., Kao, C.-H., Liu, S.-Y., Wang, J., & Sung, K. C. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.3.0007 · Cited by 14
The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research
WALSH, S. L., & Babalonis, S. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_448 · Cited by 14
Self-citation
Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence
WINSTOCK, A. R., Lea, T., Madden, A., & Bath, N. (2008) · Drugs Education Prevention and Policy · doi:10.1080/09687630701425865 · Cited by 14

Authors: Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L.
Affiliations: Johns Hopkins University (US)
ORCID: Walsh, S L
Preston, K L
Stitzer, M L
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 1995-07
Volume: 274
Issue: 1
Pages: 361-372
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1016/s0022-3565(25)10510-7
OpenAlex: W2097145370
Cited by: 283
References: 0
Citations by year: 2025: 6 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 12 · 2019: 12 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 11
FWCI: 9.36
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
PubMed
Funders: National Institutes of Health (5r18da006165-05, 5r18da006120-05)
National Institute on Drug Abuse (R18 DA 06165, K05DA000050, R18 DA06120)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords: buprenorphine, methadone, opioid agonist-antagonist, opioid blockade, opioid use disorder, opioid abuse, sublingual administration, dose-response relationship, ceiling effect, respiratory depression, miosis, euphoria, sedation, abuse liability
MeSH terms: Adult, Buprenorphine, Hydromorphone, Double-Blind Method, Humans, Male, Methadone, Narcotic Antagonists, Receptors, Opioid, Respiration, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks